[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
The newspaper knows that Clinical trials can begin with Richter on Monday, the company’s application was received by the pharmaceutical authority on Saturday.
As is known, a few days ago the news came that Richter had completed the synthesis of the active ingredient remdesivir, which he had also manufactured, in five months.
Mátyás Szentiványi, general director of the National Institute of Pharmacy and Food Health (OGYÉI), told the portal before being informed on Saturday.
It is a great thing that this preparation is finally available in Hungary as a product from a national manufacturer, the CEO of OGYÉI now told the newspaper, who also emphasized that it is not yet available to the public, as the drug is before the procedure. authorization.
The drug will be available as part of the clinical trial in the hospitals where permission was requested.
Mátyás Szentiványi said that in Hungary, these products have priority during authorization: “we can shorten the evaluation time, but at the same time we cannot relax the professional requirements for patient safety.”
Cover image: illustration. Source: Getty Images
[ad_2]
